The core objective of this work was to formulate nanoemulgel containing tolnaftate loaded for sustained delivery of the treatment of onychomycosis. Onychomycosis was not regarded as a serious infection until quite recently. The oral antifungal therapy for onychomycosis usually lasts long and brings a set of adverse effects, especially hepato-toxicity and drug interactions. The incidence of onychomycosis in with more prevalent in warm humid climates topical therapy is usually prescribed only in mild cases. It prevails among around 5% of the total world population and affects toenails much more than fingernails. The incidence of onychomycosis with more prevalent in warm humid climates so an attempt has been made to develop nanoemulsion containing tolnaftate. Formulations were optimized by factorial design. Developed formulations were evaluated and characterized for drug content-96.72, in-vitro release study-68.42%, SEM study. Based on the drug content, in-vitro release study, and SEM study, the optimized formulation was converted into nanoemulgel. The developed topical nanoemulgel was evaluated for the determination of pH 6.60, determination of spreadability 17.77 g.cm/sec, measurement of viscosity 12350 cp, drug content Study 96.52%, in-vitro drug release study 70.42% found to be effective and producing a sustained effect.
Read full abstract